Skip to main content

Influence of Conformationally Constrained Amino Acids Replacing Positions 2 and 3 of Arginine Vasopressin (AVP) and Its Analogues on Their Pharmacological Properties

Buy Article:

$63.00 plus tax (Refund Policy)

Synthesis of thirteen new analogues of arginine vasopressin (AVP) has been described. Amino acid residues at positions 2 and 3 of AVP, [3-mercaptopropionic acid (Mpa)1]AVP (dAVP), [Mpa1,D-Arg8]VP (dDAVP) and [Mpa1,Val4,D-Arg8]VP (dVDAVP) were replaced with one amino acid residue using sterically constrained nonproteinogenic amino acids, 4-aminobenzoic acid (Abz), cis-4-aminocyclohexanecarboxylic acid (ach) or its trans-isomer (Ach). In the case of a potent V1a antagonist, [1-mercaptocyclohexaneacetic acid (Cpa)1]AVP, only one similar analogue has been prepared by replacing positions 2 and 3 with Abz. Unfortunately, all new peptides were inactive in bioassays for the pressor, antidiuretic and uterotonic in vitro activities in the rat.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: 4-aminobenzoic acid (Abz); Analogues of arginine vasopressin (AVP); biological activity; cis-4-aminocyclohexanecarboxylic acid(ach); trans-4-aminocyclohexanecarboxylic acid (Ach)

Document Type: Research Article

Affiliations: Faculty of Chemistry, University of Gda sk, Sobieskiego 18, 80-952 Gda sk, Poland.

Publication date: 2007-03-01

More about this publication?
  • Protein & Peptide Letters publishes short papers in all important aspects of protein and peptide research, including structural studies, recombinant expression, function, synthesis, enzymology, immunology, molecular modeling, drug design etc. Manuscripts must have a significant element of novelty, timeliness and urgency that merit rapid publication. Reports of crystallisation, and preliminary structure determinations of biologically important proteins are acceptable. Purely theoretical papers are also acceptable provided they provide new insight into the principles of protein/peptide structure and function.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more